Melanoma is one of the serious types of skin cancers that develops from pigment-containing cells called as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are most common on the back. Moles, brown spots and growths on the skin are found to be the symptoms associated with the disease. When it spreads to other places in body, it's called metastatic, or advanced. Although in many cases metastatic melanoma can?t be cured, treatments and support can help people live longer and better. Doctors have therapies that have greatly increased survival rates. And researchers are working to find new medications that can do even more.
This report aims to provide a comprehensive presentation of the global market for Metastatic Melanoma Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metastatic Melanoma Diagnostic. This report contains market size and forecasts of Metastatic Melanoma Diagnostic in global, including the following market information:
Global Metastatic Melanoma Diagnostic Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Metastatic Melanoma Diagnostic market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
BRAF Mutation Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Metastatic Melanoma Diagnostic include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metastatic Melanoma Diagnostic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metastatic Melanoma Diagnostic Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, by Type, 2022 (%)
BRAF Mutation
Circulating Tumor Cells (CTCs)
Immunohistochemistry
Others
Global Metastatic Melanoma Diagnostic Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, by Application, 2022 (%)
Pathology Laboratories
Hospitals
Cancer Research Centres
Others
Global Metastatic Melanoma Diagnostic Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metastatic Melanoma Diagnostic revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Metastatic Melanoma Diagnostic revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Metastatic Melanoma Diagnostic, market overview.
Chapter 2: Global Metastatic Melanoma Diagnostic market size in revenue.
Chapter 3: Detailed analysis of Metastatic Melanoma Diagnostic company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metastatic Melanoma Diagnostic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Metastatic Melanoma Diagnostic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metastatic Melanoma Diagnostic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metastatic Melanoma Diagnostic Overall Market Size
2.1 Global Metastatic Melanoma Diagnostic Market Size: 2022 VS 2030
2.2 Global Metastatic Melanoma Diagnostic Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Metastatic Melanoma Diagnostic Players in Global Market
3.2 Top Global Metastatic Melanoma Diagnostic Companies Ranked by Revenue
3.3 Global Metastatic Melanoma Diagnostic Revenue by Companies
3.4 Top 3 and Top 5 Metastatic Melanoma Diagnostic Companies in Global Market, by Revenue in 2022
3.5 Global Companies Metastatic Melanoma Diagnostic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Metastatic Melanoma Diagnostic Players in Global Market
3.6.1 List of Global Tier 1 Metastatic Melanoma Diagnostic Companies
3.6.2 List of Global Tier 2 and Tier 3 Metastatic Melanoma Diagnostic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Metastatic Melanoma Diagnostic Market Size Markets, 2022 & 2030
4.1.2 BRAF Mutation
4.1.3 Circulating Tumor Cells (CTCs)
4.1.4 Immunohistochemistry
4.1.5 Others
4.2 By Type - Global Metastatic Melanoma Diagnostic Revenue & Forecasts
4.2.1 By Type - Global Metastatic Melanoma Diagnostic Revenue, 2018-2023
4.2.2 By Type - Global Metastatic Melanoma Diagnostic Revenue, 2024-2030
4.2.3 By Type - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Metastatic Melanoma Diagnostic Market Size, 2022 & 2030
5.1.2 Pathology Laboratories
5.1.3 Hospitals
5.1.4 Cancer Research Centres
5.1.5 Others
5.2 By Application - Global Metastatic Melanoma Diagnostic Revenue & Forecasts
5.2.1 By Application - Global Metastatic Melanoma Diagnostic Revenue, 2018-2023
5.2.2 By Application - Global Metastatic Melanoma Diagnostic Revenue, 2024-2030
5.2.3 By Application - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Metastatic Melanoma Diagnostic Market Size, 2022 & 2030
6.2 By Region - Global Metastatic Melanoma Diagnostic Revenue & Forecasts
6.2.1 By Region - Global Metastatic Melanoma Diagnostic Revenue, 2018-2023
6.2.2 By Region - Global Metastatic Melanoma Diagnostic Revenue, 2024-2030
6.2.3 By Region - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Metastatic Melanoma Diagnostic Revenue, 2018-2030
6.3.2 US Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.3.3 Canada Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.3.4 Mexico Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Metastatic Melanoma Diagnostic Revenue, 2018-2030
6.4.2 Germany Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.4.3 France Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.4.4 U.K. Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.4.5 Italy Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.4.6 Russia Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.4.7 Nordic Countries Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.4.8 Benelux Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Metastatic Melanoma Diagnostic Revenue, 2018-2030
6.5.2 China Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.5.3 Japan Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.5.4 South Korea Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.5.5 Southeast Asia Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.5.6 India Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Metastatic Melanoma Diagnostic Revenue, 2018-2030
6.6.2 Brazil Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.6.3 Argentina Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Metastatic Melanoma Diagnostic Revenue, 2018-2030
6.7.2 Turkey Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.7.3 Israel Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.7.4 Saudi Arabia Metastatic Melanoma Diagnostic Market Size, 2018-2030
6.7.5 UAE Metastatic Melanoma Diagnostic Market Size, 2018-2030
7 Metastatic Melanoma Diagnostic Companies Profiles
7.1 Myriad Genetics
7.1.1 Myriad Genetics Company Summary
7.1.2 Myriad Genetics Business Overview
7.1.3 Myriad Genetics Metastatic Melanoma Diagnostic Major Product Offerings
7.1.4 Myriad Genetics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.1.5 Myriad Genetics Key News & Latest Developments
7.2 Abbott Laboratories
7.2.1 Abbott Laboratories Company Summary
7.2.2 Abbott Laboratories Business Overview
7.2.3 Abbott Laboratories Metastatic Melanoma Diagnostic Major Product Offerings
7.2.4 Abbott Laboratories Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.2.5 Abbott Laboratories Key News & Latest Developments
7.3 Foundation Medicine
7.3.1 Foundation Medicine Company Summary
7.3.2 Foundation Medicine Business Overview
7.3.3 Foundation Medicine Metastatic Melanoma Diagnostic Major Product Offerings
7.3.4 Foundation Medicine Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.3.5 Foundation Medicine Key News & Latest Developments
7.4 Pathway Genomics Corporation
7.4.1 Pathway Genomics Corporation Company Summary
7.4.2 Pathway Genomics Corporation Business Overview
7.4.3 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Major Product Offerings
7.4.4 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.4.5 Pathway Genomics Corporation Key News & Latest Developments
7.5 Cancer Genetics
7.5.1 Cancer Genetics Company Summary
7.5.2 Cancer Genetics Business Overview
7.5.3 Cancer Genetics Metastatic Melanoma Diagnostic Major Product Offerings
7.5.4 Cancer Genetics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.5.5 Cancer Genetics Key News & Latest Developments
7.6 Castle Biosciences
7.6.1 Castle Biosciences Company Summary
7.6.2 Castle Biosciences Business Overview
7.6.3 Castle Biosciences Metastatic Melanoma Diagnostic Major Product Offerings
7.6.4 Castle Biosciences Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.6.5 Castle Biosciences Key News & Latest Developments
7.7 NeoGenomics
7.7.1 NeoGenomics Company Summary
7.7.2 NeoGenomics Business Overview
7.7.3 NeoGenomics Metastatic Melanoma Diagnostic Major Product Offerings
7.7.4 NeoGenomics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.7.5 NeoGenomics Key News & Latest Developments
7.8 Dermtech
7.8.1 Dermtech Company Summary
7.8.2 Dermtech Business Overview
7.8.3 Dermtech Metastatic Melanoma Diagnostic Major Product Offerings
7.8.4 Dermtech Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.8.5 Dermtech Key News & Latest Developments
7.9 Sysmex Inostics
7.9.1 Sysmex Inostics Company Summary
7.9.2 Sysmex Inostics Business Overview
7.9.3 Sysmex Inostics Metastatic Melanoma Diagnostic Major Product Offerings
7.9.4 Sysmex Inostics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
7.9.5 Sysmex Inostics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Metastatic Melanoma Diagnostic Market Opportunities & Trends in Global Market
Table 2. Metastatic Melanoma Diagnostic Market Drivers in Global Market
Table 3. Metastatic Melanoma Diagnostic Market Restraints in Global Market
Table 4. Key Players of Metastatic Melanoma Diagnostic in Global Market
Table 5. Top Metastatic Melanoma Diagnostic Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Metastatic Melanoma Diagnostic Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Metastatic Melanoma Diagnostic Revenue Share by Companies, 2018-2023
Table 8. Global Companies Metastatic Melanoma Diagnostic Product Type
Table 9. List of Global Tier 1 Metastatic Melanoma Diagnostic Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metastatic Melanoma Diagnostic Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Metastatic Melanoma Diagnostic Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Metastatic Melanoma Diagnostic Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Metastatic Melanoma Diagnostic Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Metastatic Melanoma Diagnostic Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Metastatic Melanoma Diagnostic Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Metastatic Melanoma Diagnostic Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2024-2030
Table 30. Myriad Genetics Company Summary
Table 31. Myriad Genetics Metastatic Melanoma Diagnostic Product Offerings
Table 32. Myriad Genetics Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 33. Myriad Genetics Key News & Latest Developments
Table 34. Abbott Laboratories Company Summary
Table 35. Abbott Laboratories Metastatic Melanoma Diagnostic Product Offerings
Table 36. Abbott Laboratories Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 37. Abbott Laboratories Key News & Latest Developments
Table 38. Foundation Medicine Company Summary
Table 39. Foundation Medicine Metastatic Melanoma Diagnostic Product Offerings
Table 40. Foundation Medicine Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 41. Foundation Medicine Key News & Latest Developments
Table 42. Pathway Genomics Corporation Company Summary
Table 43. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product Offerings
Table 44. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 45. Pathway Genomics Corporation Key News & Latest Developments
Table 46. Cancer Genetics Company Summary
Table 47. Cancer Genetics Metastatic Melanoma Diagnostic Product Offerings
Table 48. Cancer Genetics Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 49. Cancer Genetics Key News & Latest Developments
Table 50. Castle Biosciences Company Summary
Table 51. Castle Biosciences Metastatic Melanoma Diagnostic Product Offerings
Table 52. Castle Biosciences Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 53. Castle Biosciences Key News & Latest Developments
Table 54. NeoGenomics Company Summary
Table 55. NeoGenomics Metastatic Melanoma Diagnostic Product Offerings
Table 56. NeoGenomics Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 57. NeoGenomics Key News & Latest Developments
Table 58. Dermtech Company Summary
Table 59. Dermtech Metastatic Melanoma Diagnostic Product Offerings
Table 60. Dermtech Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 61. Dermtech Key News & Latest Developments
Table 62. Sysmex Inostics Company Summary
Table 63. Sysmex Inostics Metastatic Melanoma Diagnostic Product Offerings
Table 64. Sysmex Inostics Metastatic Melanoma Diagnostic Revenue (US$, Mn) & (2018-2023)
Table 65. Sysmex Inostics Key News & Latest Developments
List of Figures
Figure 1. Metastatic Melanoma Diagnostic Segment by Type in 2022
Figure 2. Metastatic Melanoma Diagnostic Segment by Application in 2022
Figure 3. Global Metastatic Melanoma Diagnostic Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Metastatic Melanoma Diagnostic Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Metastatic Melanoma Diagnostic Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Metastatic Melanoma Diagnostic Revenue in 2022
Figure 8. By Type - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 9. By Application - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 10. By Type - Global Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 12. By Application - Global Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 14. By Region - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 15. By Country - North America Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 16. US Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 20. Germany Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 21. France Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 28. China Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 32. India Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 34. Brazil Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2030
Figure 37. Turkey Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Metastatic Melanoma Diagnostic Revenue, (US$, Mn), 2018-2030
Figure 41. Myriad Genetics Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Abbott Laboratories Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Foundation Medicine Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Cancer Genetics Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Castle Biosciences Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. NeoGenomics Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Dermtech Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Sysmex Inostics Metastatic Melanoma Diagnostic Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
